Synmosa Biopharma Corporation (TPEX:4114)

Synmosa Biopharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,154	1,186	918.56	1,088	868.17	638.35
Short-Term Investments	388.14	120.31	520	310	115	100
Trading Asset Securities	744.49	575.94	211.45	20.1	5.26	7.01
Cash & Short-Term Investments	3,287	1,882	1,650	1,418	988.43	745.35
Cash Growth	79.47%	14.08%	16.38%	43.43%	32.61%	30.74%
Accounts Receivable	1,300	1,252	1,155	1,125	799.64	702.53
Other Receivables	3.66	57.88	48.43	20.86	10.47	16.31
Receivables	1,303	1,310	1,203	1,146	810.11	718.84
Inventory	2,028	1,787	1,651	1,384	1,214	1,239
Prepaid Expenses	161.68	34.54	28.1	-	51.11	47.23
Other Current Assets	4.93	5.31	7	60.84	35.05	231.46
Total Current Assets	6,784	5,019	4,539	4,008	3,099	2,982
Property, Plant & Equipment	5,623	5,589	5,557	5,638	5,662	5,788
Long-Term Investments	317.47	336.48	222.87	223.01	303.48	271.52
Goodwill	-	62.29	62.29	71.08	7.27	13.27
Other Intangible Assets	472.15	449.22	496.56	496.8	494.03	536.69
Long-Term Deferred Tax Assets	377.47	363.27	330.56	331.78	329.28	311.7
Other Long-Term Assets	484.26	484.54	519.9	433.53	421.53	473.71
Total Assets	14,059	12,304	11,729	11,203	10,317	10,377
Accounts Payable	541.14	471.02	427.54	446.16	249.58	184.26
Accrued Expenses	-	443.36	381.68	368.47	264.64	260.62
Short-Term Debt	795.49	674.89	661.22	584.08	763.77	630.76
Current Portion of Long-Term Debt	128.87	72.33	289.39	584.42	413.9	256.53
Current Portion of Leases	22.3	22.94	23.3	16.7	6.74	6.83
Current Income Taxes Payable	121.27	142.57	118.29	95.54	53.18	54.61
Current Unearned Revenue	159.6	163.72	172.29	173.43	126.87	129.31
Other Current Liabilities	743.76	83.76	44.71	53.91	10.21	36.74
Total Current Liabilities	2,512	2,075	2,118	2,323	1,889	1,560
Long-Term Debt	1,681	1,729	1,400	2,122	2,272	2,804
Long-Term Leases	40.57	49.86	58.66	48.42	6.76	3.84
Long-Term Unearned Revenue	8.84	5.53	2.35	-	-	-
Long-Term Deferred Tax Liabilities	29.57	37.42	35.45	34.52	34.2	35.11
Other Long-Term Liabilities	8.01	1.26	0.53	12.62	0.89	0.86
Total Liabilities	4,281	3,905	3,628	4,554	4,221	4,423
Common Stock	4,643	4,293	4,014	3,437	3,131	2,808
Additional Paid-In Capital	2,693	2,082	2,195	1,425	1,426	1,403
Retained Earnings	879.79	1,096	1,092	1,005	613.43	713.49
Treasury Stock	-187.73	-205.68	-486.96	-486.96	-402.62	-350.87
Comprehensive Income & Other	371.69	-55.82	-104.78	-68.18	-63.04	-73.45
Total Common Equity	8,400	7,210	6,710	5,312	4,706	4,500
Minority Interest	1,378	1,189	1,391	1,337	1,390	1,455
Shareholders' Equity	9,778	8,399	8,101	6,649	6,095	5,955
Total Liabilities & Equity	14,059	12,304	11,729	11,203	10,317	10,377
Total Debt	2,668	2,549	2,433	3,355	3,463	3,702
Net Cash (Debt)	618.11	-666.47	-782.59	-1,937	-2,474	-2,956
Net Cash Per Share	1.30	-1.44	-1.75	-4.49	-5.69	-6.96
Filing Date Shares Outstanding	495.66	462.21	462.21	429.15	432.91	436.18
Total Common Shares Outstanding	495.66	462.21	462.21	429.15	432.91	436.18
Working Capital	4,272	2,945	2,421	1,686	1,210	1,423
Book Value Per Share	16.95	15.60	14.52	12.38	10.87	10.32
Tangible Book Value	7,928	6,699	6,151	4,744	4,204	3,950
Tangible Book Value Per Share	15.99	14.49	13.31	11.05	9.71	9.06
Land	-	3,528	3,528	3,558	3,558	3,567
Buildings	-	1,587	1,567	1,558	1,542	1,561
Machinery	-	2,050	1,893	1,790	1,696	1,728
Construction In Progress	-	89.55	19.08	9.74	62.51	47.32
Leasehold Improvements	-	83.19	80.49	78.96	22.62	19.93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.